

mBC Summit 2018 1 September 2018 Conrad Hong Kong

SAVE THE DATE

Metastatic Breast Cancer (mBC) Summit 9:00 AM - 4:30 PM | Saturday, 1 September 2018 | Hong Kong

These are optimistic times to be a breast oncologist. Treatment for mBC has improved significantly over the last decade.

Becoming a breast oncologist in the molecular era of medicine is challenging, especially in formulating the best treatment plan for patients. The 2018 mBC Summit, guided by a scientific steering committee in collaboration with the Hong Kong Breast Oncology Group, will feature keynote address by Professor William Gradishar, as well as exciting presentations by regional and local experts. By bringing together key opinion leaders in breast oncology, this summit will provide a platform for discussions around novel treatments and latest clinical evidence in mBC management particularly in Asian patients, as well as enable collaboration and exchange of expertise and experience.

Steering committee



Professor Roger Ngan President Hong Kong Breast Oncology Group Clinical Professor Department of Clinical Oncology The University of Hong Kong Hong Kong



Dr Janice Tsang Founding Convenor Hong Kong Breast Oncology Group Honorary Clinical Assistant Professor Department of Clinical Oncology The University of Hong Kong Hong Kong

Keynote international speaker



Professor William Gradishar Chief of Hematology and Oncology Department of Medicine Northwestern University Feinberg School of Medicine Chicago, USA

Regional speakers



Professor Seock-Ah Im Professor of Medical Oncology Department of Internal Medicine Seoul National University Hospital Seoul, Korea



Dr Yen-Shen Lu Clinical Associate Professor Department of Internal Medicine National Taiwan University College of Medicine Taipei, Taiwan



Dr Sachin Almel Consultant Medical Oncologist P.D. Hinduja National Hospital and Medical Research Centre Mumbai, India

Join us at the Conrad Hong Kong for the 2018 mBC Summit.

Please contact your Pfizer representative for more information. See you there!


















mBC Summit 2018

1 September 2018 Conrad Hong Kong

Metastatic Breast Cancer (mBC) Summit 2018

Closing the gaps in breast cancer patient care through innovation

9:00 AM - 4:30 PM | Saturday, 1 September 2018 | Conrad Hong Kong

	AGENDA	
08:30	Arrivals and registration	
09:00	Welcome and introductions	<u>Co-chairs:</u> Roger Ngan (HK) Janice Tsang (HK)
-	session 1	
	co-chairs: Janice Tsang and Roger Ngan (HK)	
	advances in metastatic breast cancer (mBC) management	
09:10	Keynote address: Shaping the treatment paradigm for HR+ HER2- mBC patients	William Gradishar (USA)
10:00	Are we ready for the prognostic and predictive role of genomic profiling in breast cancer?	Yen-Shen Lu (Taiwan)
10:30	Q&A	
10:45	BREAK	
HR+ HE	R2- breast cancer: Current landscape and treatment paradigms in Asia	
11:00	Identifying gaps and opportunities in the mBC landscape in Asia	Seock-Ah Im (Korea)
11:25	Treatment considerations for HR+ HER2- mBC patients in Asia: First-line and beyond	Seock-Ah Im (Korea)
11:50	Panel discussion	William Gradishar (USA)
	Optimizing the management of HR+ HER2- mBC in Asia: Are we on par with the	Yen-Shen Lu (Taiwan)
	rest of the world?	Seock-Ah Im (Korea)
12:05	LUNCH	
Experie	nce sharing	
Session	co-chairs: Mai-Yee Luk and Joyce Suen (HK)	
The ma	nagement of HR+ HER2- mBC across different patient settings	
12:55	Case 1: Managing the premenopausal HR+ HER2- mBC patient	Carol Kwok (HK)
13:25	Case 2: Treatment of the de novo mBC patient with visceral metastases	Sachin Almel (India)
13:55	Case 3: Postmenopausal patient progressing on aromatase inhibitor	Cindy Wong (HK)
14:25	Panel discussion	William Gradishar (USA)
	The CDK4/6 inhibitors conundrum: How do I choose and which should I use?	Yen-Shen Lu (Taiwan) Case presenters
14:55	BREAK	1











mBC Summit 2018

1 September 2018 Conrad Hong Kong

_	co-chairs: Ting Ying Ng and Carol Kwok (HK)	
Manag	ng other breast cancer subtypes	
15:05	Genetic testing and treatment strategies in breast cancer in the era of NGS Part 1: Genetic testing in hereditary and somatic breast cancers Part 2: Optimizing pharmacological management	Ava Kwong (HK) Joanne Chiu (HK)
15:35 15:50	HER2+ breast cancer: Are there other targets beyond HER2? Q&A	Roland Leung (HK)
A peek	into the future: What should we expect in the next decade?	
16:05	Panel discussion The changing face of metastatic breast cancer management	William Gradishar (USA) Sachin Almel (India) Yen-Shen Lu (Taiwan) Roger Ngan (HK) Janice Tsang (HK)
16:25	Summary and closing	Roger Ngan (HK) Janice Tsang (HK)
16:30	Meeting close	











